$11.03−0.09 (−0.81%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
AbCellera Biologics (ABCL) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
46 figures withheld by our checks. Each blank figure names its reason.
Business engineChoppy: revenue is 85% below its peak, net margin −194.9%.
The four lines that matter · FY21–FY25
Revenue ($M)▲160.6%
75.1
FY21→FY25CAGR −33.1%/yr
Net income ($M)▲10.1%
−146.4
one-off year: see footnoteCAGR —
Free cash flow ($M)▲6.9%
−174.1
FY21→FY25CAGR —
Diluted EPS▲10.9%
−0.49
buyback-liftedCAGR —
What the receipts whisper · what a headline number hides
Share count
−6.2%
318.3mn → 298.7mn diluted shares since FY21. Part of EPS growth is the shrinking denominator. Watch net income too.
Capex
$42.8M
−45.4% YoY in FY25 · 56.9% of revenue.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-195¢ of every revenue dollar becomes profit.
Margin trend · direction beats level Gross Operating Net
Net margin -194.9% is below the sector median.
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 67.9 | 75.1 | 28.8 | 38.0 | 485.4 | 375.2 | ▲160.6% | −33.1% |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | —A | —A | —A | —A | —A | 375.2 | — | — |
Research & development | 186.3 | 186.8 | 167.3 | 175.7 | 107.9 | 62.1 | ▲11.7% | +31.7% |
Selling, general & admin | 57.0 | 83.2 | 85.5 | 75.2 | 55.5 | 41.8 | ▼2.6% | +18.8% |
Total operating expenses | 270.0 | 292.2 | 343.6 | 275.2 | 268.9 | 170.8 | ▼14.9% | +14.4% |
Operating incomefeeds ROC rank | −202.2 | −217.1 | −314.8 | −237.2 | 216.5 | 204.4 | ▲31.0% | — |
Other income, net | 31.4 | 39.5 | 114.4 | 63.2 | 22.6 | 14.7 | — | — |
Pretax income | −170.8 | −177.6 | −200.4 | −174.0 | 239.1 | 219.1 | ▲11.4% | — |
Income tax | −22.5 | −31.2 | −37.5 | −27.6 | 80.6 | 65.7 | ▲16.9% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −148.3 | −146.4 | −162.9 | −146.4 | 158.5 | 153.5 | ▲10.1% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −0.48 | −0.49 | −0.55 | −0.51 | 0.50 | 0.48 | ▲10.9% | — |
Diluted shares (mn) | 318.05 | 298.71 | 294.33 | 289.17 | 314.83 | 318.29 | ▲1.5% | −1.6% |
| Margins | ||||||||
Gross margin | —A | —A | —A | —A | —A | 100.0% | — | — |
Operating margin | −298.0% | −289.0% | −1091.7% | −623.8% | 44.6% | 54.5% | ▲802.7pp | −343.5pp |
Net margin7th pct in Healthcare | −218.5% | −194.9% | −564.8% | −385.0% | 32.7% | 40.9% | ▲369.9pp | −235.8pp |
† TTM = trailing four quarters through 2026-09-30.FY21 effective tax rate was 30% vs a 19% norm for this window, likely a one-time item; see the filing.FY22 effective tax rate was 34% vs a 19% norm for this window, likely a one-time item; see the filing.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-24 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was AbCellera Biologics' revenue last fiscal year?
AbCellera Biologics reported revenue of $75.1M in fiscal 2025, up 160.6% from fiscal 2024.
What was AbCellera Biologics' net income?
AbCellera Biologics reported net income of −$146.4M in fiscal 2025, a net margin of −194.9%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

